doubt buy out. Not enough shares traded. News makes sense based upon previous announcements. PFE stopping A-1 mimetics makes the Brewer methods more likely to be the only winner but for apoA-1 Milano IV.
I heard somewhere that Pfizer dropped the A-1 milano because they can't produce enough on a large scale. Sembiosys is developing a new production method for A-1 milano that is projected to be available in 2016, probably a little to late for Pfizer.
Don't know if production difficulties will be an issue for LIPD - I suspect not since its a much smaller peptide.
If you inject a small peptide into blood its going to get cleared by the kidney in about 2 seconds. They're going to have to associate it with some type of phospholipid complex so it doesn't get cleared quickly. If they end up doing this they're going to have to pay royalties to Pfizer since Pfizer owns the rights to this type of technology.